Search hospitals > Connecticut > Norwalk
Norwalk Hospital
Claim this profileNorwalk, Connecticut 06856
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for Adenocarcinoma
Conducts research for Serous Cystadenocarcinoma
Conducts research for Endometrioid Carcinoma
92 reported clinical trials
4 medical researchers
Summary
Norwalk Hospital is a medical facility located in Norwalk, Connecticut. This center is recognized for care of Breast Cancer, Cancer, Adenocarcinoma, Serous Cystadenocarcinoma, Endometrioid Carcinoma and other specialties. Norwalk Hospital is involved with conducting 92 clinical trials across 159 conditions. There are 4 research doctors associated with this hospital, such as Richard Frank, MD, Linus Chuang, MD, Philip Gilbo, MD, and Lisa Phuong.Area of expertise
1Breast Cancer
Global LeaderER positive
HER2 negative
Stage IV
2Cancer
Global LeaderHER2 positive
Stage III
Stage IV
Top PIs
Richard Frank, MDNorwalk Hospital1 year of reported clinical research
Studies Pancreatic Cancer
Studies Breast Cancer
18 reported clinical trials
36 drugs studied
Linus Chuang, MDNorwalk Hospital1 year of reported clinical research
Studies Endometrioid Carcinoma
Studies Serous Cystadenocarcinoma
5 reported clinical trials
11 drugs studied
Philip Gilbo, MDNorwalk Hospital4 years of reported clinical research
Studies Breast Cancer
Studies Breast Carcinoma
2 reported clinical trials
3 drugs studied
Lisa PhuongNorwalk Hospital1 year of reported clinical research
Studies Breast Cancer
1 reported clinical trial
6 drugs studied
Clinical Trials running at Norwalk Hospital
Breast Cancer
Pancreatic Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Adenocarcinoma
Prostate Cancer
Follicular Lymphoma
Small Cell Lung Cancer
Ductal Carcinoma In Situ
Omitting Radiation Therapy
for Breast Cancer
This study is evaluating whether a type of radiation therapy may help prevent breast cancer from coming back.
Recruiting2 awards Phase 319 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
PF-07220060 + Fulvestrant
for Advanced Breast Cancer
The purpose of this study is to learn about the safety and how effective the study medicine (PF-07220060) plus fulvestrant is compared to the study doctor's choice of treatment in people with advanced or metastatic breast cancer. Advanced cancer is the one that is unlikely to be cured or taken care of with treatment. Metastatic cancer is the one that has spread to other parts of the body. This study is seeking female and male participants who: are 18 years of age or older; are hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative; have advanced or metastatic breast cancer after taking other treatments before this study; have not taken or need to take medications that are not allowed by the study protocol; do not have any medical or mental conditions that may increase the risk of study participation. Half of the participants will take PF-07220060 two times daily by mouth along with fulvestrant. Fulvestrant will be given as a shot into the muscle. The other half will take the study doctor's choice of treatment which can either be: Fulvestrant alone taken as shot into the muscle. Everolimus along with exemestane taken once daily by mouth. This study will compare the experiences of participants receiving the study medicine plus fulvestrant to those who are receiving the study doctor's choice of treatment. This will help decide if the study medicine is safe and effective. Participants will receive study treatment and/or will be in the study until: imaging scans (such as an MRI and/or CT) show that their cancer is getting worse. the study doctor thinks the participant is no longer benefitting from the study medicine. has side effects that become too severe. A side effect is a reaction (expected or unexpected) to a medicine or treatment you take. the participant chooses to stop taking part.
Recruiting2 awards Phase 3
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Norwalk Hospital?
Norwalk Hospital is a medical facility located in Norwalk, Connecticut. This center is recognized for care of Breast Cancer, Cancer, Adenocarcinoma, Serous Cystadenocarcinoma, Endometrioid Carcinoma and other specialties. Norwalk Hospital is involved with conducting 92 clinical trials across 159 conditions. There are 4 research doctors associated with this hospital, such as Richard Frank, MD, Linus Chuang, MD, Philip Gilbo, MD, and Lisa Phuong.